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Abstract. Limiting dietary carbohydrates inhibits glioma 
growth in preclinical models. Therefore, the ERGO trial 
(NCT00575146) examined feasibility of a ketogenic diet in 
20 patients with recurrent glioblastoma. Patients were put 
on a low-carbohydrate, ketogenic diet containing plant oils. 
Feasibility was the primary endpoint, secondary endpoints 
included the percentage of patients reaching urinary ketosis, 
progression-free survival (PFS) and overall survival. The 
effects of a ketogenic diet alone or in combination with 
bevacizumab was also explored in an orthotopic U87MG 
glioblastoma model in nude mice. Three patients (15%) 
discontinued the diet for poor tolerability. No serious adverse 
events attributed to the diet were observed. Urine ketosis was 
achieved at least once in 12 of 13 (92%) evaluable patients. 
One patient achieved a minor response and two patients 
had stable disease after 6 weeks. Median PFS of all patients 
was 5 (range, 3-13) weeks, median survival from enrollment 
was 32 weeks. The trial allowed to continue the diet beyond 
progression. Six of 7 (86%) patients treated with bevacizumab 
and diet experienced an objective response, and median PFS 
on bevacizumab was 20.1 (range, 12-124) weeks, for a PFS 
at 6 months of 43%. In the mouse glioma model, ketogenic 
diet alone had no effect on median survival, but increased that 
of bevacizumab-treated mice from 52 to 58 days (p<0.05). 
In conclusion, a ketogenic diet is feasible and safe but prob-
ably has no significant clinical activity when used as single 
agent in recurrent glioma. Further clinical trials are neces-
sary to clarify whether calorie restriction or the combination 
with other therapeutic modalities, such as radiotherapy or 
anti-angiogenic treatments, could enhance the efficacy of the 
ketogenic diet.
Introduction
The majority of solid tumors is characterized by increased 
glucose uptake and can therefore be detected by 18F-fluorodeoxy-
glucose positron emission tomography (FDG-PET). On a 
cellular basis, this is reflected by elevated glycolysis even in 
the presence of oxygen (aerobic glycolysis, the Warburg effect 
(1). There is also evidence of increased glycolysis in glioblas-
toma. First, malignant gliomas are characterized by activation 
of growth factor receptor/PI3 kinase/Akt signaling (2) leading 
to increased reliance on glycolysis (3) and by loss of p53 
wild-type activity which can result in reduced expression of 
synthesis of cytochrome C oxidase 2 (SCO2), necessary for 
the proper assembly and function of the mitochondrial respira-
tory chain (4,5), and of tp53-induced glycolysis and apoptosis 
regular (TIGAR), which suppresses glycolysis (6,7). Second, 
hypoxia typically present in malignant glioma is expected to 
stimulate accumulation of HIF-1α and subsequent expression 
of genes involved in glucose metabolism and in the suppression 
of oxidative phosphorylation (8, 9). Indeed, there is evidence of 
HIF-1α and glucose transporter 3 (GLUT3) expression (10) and 
of increased lactate accumulation in malignant gliomas (11). 
Further, FDG-PET and 18F-fluoromisonidazole (FMISO)-PET 
showed increased glucose uptake and hypoxia in malignant 
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gliomas (12,13). Recently, innovative metabolic flux analyses 
confirmed increased glucose metabolism in glioblastoma tissue 
(14) and mouse xenograft tumors (15). Interestingly, glucose is 
metabolized not only to lactate, but also via the tricarboxylic 
acid (TCA) cycle (14-16) possibly providing proliferating cells 
with carbon precursors for anabolic metabolism. Additionally, 
glucose is metabolized by the pentose phosphate pathway 
thereby providing riboses for nucleic acid synthesis and 
producing NADPH which is involved in antioxidative defense 
mechanisms (17).
Apart from the tumor-intrinsic consequences of increased 
glycolysis, glucose metabolism of the whole organism seems to 
affect tumor growth. For example, elevated levels of insulin are 
associated with worse prognosis in breast cancer patients (18), 
and increased insulin-like growth factor-1 (IGF-1) levels are 
associated with an elevated risk of prostate (19,20) and breast 
cancer (21). These observations may relate to the fact that 
insulin and IGF-1 not only modulate glucose metabolism of 
healthy tissues but also act as growth factors for tumor cells. 
The influence of insulin on tumor formation and growth is 
supported by epidemiologic analyses where tumor rates were 
higher in diabetic patients treated with insulin-releasing drugs 
such as sulfonylureas or with insulin, but not in patients treated 
with metformin, which does not increase insulin levels (22). 
Supporting the assumption that glucose is also important for 
glioma growth and therapy resistance, higher blood glucose 
levels are associated with worse prognosis in patients with 
glioblastoma (23).
Therefore, reducing glucose availability by dietary 
restriction of glucose and carbohydrates might affect tumor 
growth. Such a restriction can be achieved by a ketogenic diet, 
characterized by low carbohydrate intake and high fat and 
balanced protein content. In this situation, ketone bodies such 
as acetoacetate and 3-hydroxybutyrate (3-OHB) are produced 
which serve as alternative energy substrates for brain cells. 
In different murine xenograft models, ketogenic diets inhibit 
tumor growth (24-26). Clinically, the ketogenic diet is an 
effective treatment for children and probably also for adults 
with refractory epilepsy (27). These diets reduce body weight 
in obese patients, modulate blood lipid profiles (28), and might 
decrease blood levels of glucose, insulin and IGF-1 (29,30). 
Only few studies on ketogenic diets in tumor patients exist. 
A description of two pediatric patients with anaplastic glioma 
indicated that a ketogenic diet might reduce tumor glucose 
uptake and inhibit tumor growth (31). Two studies on patients 
with different solid tumors showed no severe side-effects of 
ketogenic diets (32,33). No prospective registered clinical 
study on feasibility, safety and efficacy of a ketogenic diet 
in a specific tumor type and in glioma in particular has been 
reported up to now. Considering the plausible rationale for the 
ketogenic diet and the lack of established treatment options for 
recurrent glioblastoma, the ERGO study was set up to investi-
gate safety and tolerability of an unrestricted ketogenic diet in 
patients with recurrent glioblastoma.
Materials and methods
Ethics statement. The study was approved by the local 
Institutional Review Boards of the Frankfurt (no. 113/08) and 
Tübingen (no. 338/2007BO1) University hospitals. The animal 
experiment protocol was approved by the Regierungspräsidium 
Darmstadt (no. F 145/01).
Study design. This trial included patients with recurrent 
glioblastoma. Important inclusion criteria were age ≥18 years, 
detection of relapse ≥6 months after initial tumor surgery and 
≥3 months after completion of radiotherapy, relapse during or 
after temozolomide chemotherapy, no other reasonable chemo-
therapeutic option or chemotherapy refused by the patient and 
Karnofsky performancy score (KPS) of ≥60%. There were no 
restrictions concerning values of whole blood cell counts at 
inclusion. Important exclusion criteria were diabetes mellitus 
requiring insulin treatment or decompensated cardial insuf-
ficiency. The ERGO trial was an open-label, prospective, 
single-arm pilot study performed at the Frankfurt and Tübingen 
University Hospitals. The study was registered at www.
clinicaltrials.gov (NCT00575146). Patients were recruited 
between December 2007 and March 2010. Follow-up was until 
November 2011. All patients gave their written consent before 
study inclusion. At baseline and follow-up visits in 6-8-week 
intervals or if signs of clinical progression occured, medical 
history, history of seizures, KPS, mini-mental status, quality 
of life questionnaire, neurological examination, vital signs, 
laboratory parameters, adverse events and medication were 
assessed.
The primary endpoint was feasibility of the ketogenic diet 
defined as percentage of patients who discontinued diet due 
to intolerability, secondary objectives were safety of the diet, 
the percentage of patients reaching ketosis, quality of life, 
progression-free survival (PFS) and overall survival.
Treatment. The patients were put on a ketogenic diet which 
restricted carbohydrate intake to 60 g/day. In addition, highly 
fermented yoghurt drinks (500 ml per day) and two different 
plant oils (basic oil and addition oil) were provided to the 
patients and could be consumed on an individual basis. The 
drinks contained 2.42 kJ/g (0.01 g carbohydrates/g, 0.04 g 
fat/g  and 0.02 g protein/g), the energy content of the oils was 
37.3 kJ/g (0 g carbohydrates/g, 0.99 g fat/g, 0.0 g proteins/g). 
No calorie restriction was applied, and patients were 
instructed to always eat to satiety. Support for the implemen-
tation of the diet, drinks and oils were provided by Tavarlin 
(Darmstadt, Germany). Before starting the diet, the patients 
were introduced into the principles of the ketogenic diet, and 
a set of brochures with sample cooking recipes and food facts 
as well as the basic rules to follow the diet were provided. The 
patients thereafter indivually prepared their meals at home, 
no standarized eating plans were provided. The patients self-
monitored urine ketones 2-3 times per week using urine test 
sticks (Ketostix, Bayer, Germany) and filled-out a nutritional 
plan. Further, the patients were asked to complete a question-
naire covering the following aspects every week: diarrhea, 
constipation, hunger and demand for glucose. These items 
were rated from 0 (none) to 3 (strong). After 6-8 weeks or 
signs of clinical progression, disease status was assessed by 
magnetic resonance imaging using Macdonald criteria (34). 
In case of stable disease or response, patients were to continue 
the diet (Fig. 1A). In case of progression, the protocol allowed 
to continue the diet while salvage therapy was initiated. In 
case of further progression on a combination, the diet was 
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stopped. Further treatment was at discretion of the caring 
physician.
Animal experiments. The high response rate in patients exposed 
to bevacizumab upon progression while maintaining the diet 
led us to perform an exploratory trial on the combination of 
the ketogenic diet and bevacizumab in the U87MG model: 
44 female 7-week-old athymic mice (HSD:athymic nude-
Foxn1nu, Horst, The Netherlands) were maintained in groups 
of 3-4 animals per cage in a pathogen-free environment and 
given ad libitum access to food and water. All animal work was 
performed in accordance with the National Institutes of Health 
guidelines Guide for the Care and Use of Laboratory Animals 
and institutional standards. The protocol was approved by the 
Regierungspräsidium Darmstadt (no. F 145/01). On day 0 of 
the experiment, 105 human U87MG glioma cells were stereo-
tactically implanted into the right striatum. On day 7, animals 
were randomly assigned to either an unrestricted standard diet 
rich in carbohydrates or an unrestricted ketogenic diet. The 
standard diet was provided by the animal feed manufacturer 
ssniff Spezialdiaeten GmbH (Soest, Germany), the ketogenic 
diet was prepared on the basis of KetoCal® Advance (Nutricia 
GmbH, Erlangen, Germany). Diet characteristics are summa-
rized in Table I. Starting on day 12, bevacizumab (10 µg/g 
body weight, Roche, Basel, Switzerland) or phosphate-buff-
ered saline (PBS, control) were administered intraperitoneally 
twice weekly. On day 28, 12 animals, 3 per group, underwent 
MRI imaging and were subsequently sacrificed for metabolic 
bioluminescence imaging. The remaining 32 animals were 
sacrificed at the onset of neurological symptoms or weight loss 
of >20% of the body weight.
Magnetic resonance imaging (MRI) of animals. Imaging 
was performed in prone position on day 28 after tumor cell 
Figure 1. Study design and course of treatment. (A) After study inclusion, patients were treated with the ketogenic diet. At 6 weeks on the diet or in the presence 
of clinical signs of deterioration, MRI was performed. In case of at least stable disease, diet was continued. In case of a progression, the patients were offered 
salvage therapy while continuing the diet. (B) Flowchart diagram showing the course of dietary treatment in the 20 included patients.
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implantation at a 3-Tesla MRI scanner (Trio®, Siemens, 
Erlangen, Germany) using a circular polarized wrist coil and 
0.5 mmol/ml gadolinium-diethylenetriaminepentaacetic acid 
(Magnevist®, Bayer Schering Pharma, Berlin, Germany). 
Coronar T2-weighted and T1-weighted sequences were 
acquired with a slice thickness of 2 mm without gap and an 
inplane resolution of 0.2x0.2 mm. Imaging was performed 
after intraperitoneal injection of 0.3 ml of 0.5 mmol/ml 
gadolinium-diethylenetriaminepentaacetic acide (Magnevist®, 
Bayer Schering Pharma, Berlin, Germany). The largest 
perpendicular diameters of the contrast-enhancing tumor in 
the three dimensions were determined, and the tumor size was 
estimated using the ellipsoid volume formula π/6 x length x 
width x depth.
Determination of blood 3-OHB. Blood 3-OHB levels of 
randomly chosen animals (5-7 animals per group) were 
measured on day 24 in 2 µl of peripheral blood from the 
tail vein using a Precision Xtra® monitoring system (Abbott 
Laboratories, Abbott Park, IL, USA).
Metabolic mapping using bioluminescence imaging. 
Bioluminescence imaging indicating local concentrations of 
the metabolites ATP, lactate and glucose in cryosections from 
rapidly frozen brains (3 animals per group) was performed as 
previously described (35,36).
Statistical analysis. Data analysis was carried out with SPSS 
version 17.0 (IBM SPSS, Chicago, IL, USA). Significance was 
tested using the Mann-Whitney U test. Survival was estimated 
by Kaplan-Meier analysis, and differences were tested by 
Mantel-Cox log-rank statistics.
Results
Baseline characteristics. Twenty patients were enrolled 
between December 2007 and March 2010. Baseline char-
acteristics and pretreatment modalities of the patients are 
summarized in Table II. All patients had a histological diag-
nosis of glioblastoma. Primary therapy included radiotherapy 
with 60 Gy in all patients. In 16 patients (80%), radiotherapy 
was combined with concomitant temozolomide. Eighteen 
Table I. Composition of the standard and ketogenic diets for 
the animals.
Component Standard diet Ketogenic diet
Fat     6.1 56.1
Carbohydrate   55.6   2.9
Protein 21.8 15.0
Fiber   3.8   1.7
Energy (kJ/g) 15.8 23.8
Ketogenic ratio 0.08:1 3.14:1
Components of the diets used are listed in grams (g) per 100 g of 
food. The fat in both diets derived from soybean oil. The ketogenic 
diet was based on KetoCal Advance, a nutritionally complete formula 
used for children with intractable epilepsy, and supplemented with 
flaxseed and egg white. The ketogenic ratio was calculated according 
to the following formula: fats/(protein + carbohydrates).
Table II. Baseline characteristics.
Age (years) 57 (30-72)
Gender 13 female, 7 male
Number of relapses   2 (1-4)
Karnofsky performance score 85 (70-100)
Previous treatments
 Radiotherapy 20 (100%)
 Concomitant temozolomide 16   (80%)
 Temozolomide 5/28 14   (70%)
 Temozolomide 7/14 18   (90%)
 Nitrosourea-based chemotherapy   5   (25%)
 Carmustine wafer   1     (5%)
 Bevacizumab + lomustine   1     (5%)
Presented are patient characteristics at study entry. For age, number 
of relapses and KPS, median and range are presented. For previous 
therapies, the numbers and percentages of patients that received the 
denoted treatment before study entry are shown.
Table III. Clinical and laboratory parameters during the study.
  Before diet During diet
Clinical parameters
 Weight (kg) (mean ± SD) 78.3±16.1 76.5±14.6
 Mean weight difference (kg)  -1.86a
 (%)  -2.2%
 Steroids
 No 9   6
 Yes 8 11
 Median dexamethasone dose 4 (2-20) 8 (2-24)
 in mg (range)
Blood
 Glucose (mg/dl) (mean ± SD) 99±21.8 92±9.1
 No steroids, n=5 98±29.1 92±5.8
 Steroids, n=4 97±19.1 90±9.3
 HbA1c (%) (mean ± SD) 5.42 ±0.48 5.60±0.35
 Triglycerides (mg/dl) (mean ± SD) 156±69 131±56
 Cholesterol (mg/dl) (mean ± SD) 228±41 222±51
 HDL (mg/dl) 60±18 61±17
 LDL (mg/dl) 136±36 134±39
 HDL/HDL quotient 0.50±0.28 0.49±0.17
Presented are clinical and laboratory parameters at baseline and at first 
follow-up visit. Paired weight values were available in 14 patients 
(ap<0.05, paired t-test), paired blood parameters were obtained in 
11 patients. Glucose values are separately shown for the 5 patients 
not on steroids at baseline and at first follow-up, and also for the 
4 patients on steroids at both visits.
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patients (90%) were pretreated with dose-dense temozolomide 
(‘one week on/one week off’). One patient was treated with 
bevacizumab and lomustine prior to study inclusion. The 
median number of relapses, including the relapse leading to 
study inclusion, was 2 (range 1-4). The median time from the 
initial diagnosis of glioblastoma to the start of the study treat-
ment was 12.5 months (range, 6-42 months).
Feasibility. Three patients discontinued the diet in the absence 
of progression after 2-3 weeks mainly because they felt that 
carbohydrate restriction negatively affected their quality of 
life (Fig. 1B). Of the remaining 17 patients who stayed on 
diet at least until tumor progression, clinical and laboratory 
parameters before and at follow-up at a median of 36 days on 
study treatment are shown in Table III. There was a small, 
statistically significant weight loss of ~2.2% during the diet. 
A regular urine ketone analysis (at least twice a week) during 
the dietary treatment was available in 13 patients, and ketosis 
was detectable at least once in 12 of these patients (92%). In 
these, an average of 73% of the measurements documented 
ketonuria indicating rather stable ketosis in the majority of 
patients (Fig. 2).
Safety and tolerability. At least one self-reporting sheet on 
possible diet-related side-effects was available in 12 patients. 
Patients stated that they followed the diet on an average of 
6.8 days per week. No serious adverse events possibly attribut-
able to the diet, i.e., hypogylcemia, occured. The majority 
of the patients did not complain diarrhea or constipation 
(Fig. 3A and B). Hunger was present in the first week on diet 
at a mean intensity of slightly >1 (which means weakly feeling 
hungry) and decreased on the following weeks. A similar 
pattern was observed for appetence for sugar (Fig. 3C and  D).
At baseline, grade 3 leukocytopenia was present in 
2 patients and at follow-up in 1 of these patients. No other 
Figure 2. Urine ketosis. The fraction of ketone body-positive urine analyses 
(ketone bodies >0.5 mmol/l) is reported in the 13 patients with these tests 
available. Each bar represents the value of one patient, sorted from lowest 
to the highest ratios (left to right). The individual values are also presented 
above each bar.
Figure 3. Patients' self reported rating of diet tolerability. The patients were asked to fill out a self-reported questionnaire for possible diet-related side-effects 
once every week on diet. These sheets were completed at least once in 12 patients. Shown are the ratings of each patient in the categories diarrhea (A), constipa-
tion (B), hunger (C) and demand for glucose (D) in every week (dot) and the mean value of these ratings in the corresponding week (line). The scale was defined 
as follows: 0, not present; 1, weak; 2, moderate; 3, strong. Questionnaires were available in 7-11 patients at the shown time-points.
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grade 3 toxicity was observed during the study period. No 
significant changes in laboratory parameters, including blood 
glucose and HbA1c values, occurred during the diet in any of 
the analyzed parameters (Table III).
Efficacy. Median time to progression on the diet was 5 weeks 
(range, 3-13 weeks). In 3 patients, stable disease was observed 
at first follow-up at 6 weeks, and stabilization lasted for 
11, 12 and 13 weeks in these patients; one patient achieved 
a minor response (Fig. 4A and B). Median overall survival 
after start of the diet was 32 weeks (range, 6-86+ weeks). We 
further analysed whether stable ketosis might be associated 
with PFS. There was a trend for longer PFS in the group who 
had stable ketosis compared to the other patients (Fig. 5A) 
(median PFS stable ketosis (n=8) 6 weeks vs. no stable 
ketosis (n=5): 3 weeks, p=0.069, log-rank-test). To obtain 
preliminary insights into the tolerability and efficacy of the 
diet in combination with other therapies, the study protocol 
allowed the addition of a salvage therapy at first progression 
while continuing the diet. Progression was documented in all 
of 17 patients on diet. Thirteen of these received no salvage 
treatment. Eight patients continued diet with the salvage 
treatment consisting of ACNU/teniposide in 1 patient and 
bevacizumab alone (n=4) or in combination with irinotecan 
(n=3). Among these 7 patients there were 1 complete response 
and 5 partial responses (Fig. 4C), for an overall response 
rate of 85%. Median PFS from bevacizumab was 20.1 weeks 
(range, 12-124 weeks). PFS at 6 months (PFS-6) was 43%. 
We compared these results with a cohort of 28 patients who 
were treated with bevacizumab in the same period in our 
institution, but who were not on a ketogenic diet. In these, 
median PFS was 16.1 weeks (range, 4-90+ weeks; 95% CI, 
15-17 weeks), p=0.38 (log-rank-test compared to the keto-
genic diet + bevacizumab-treated patients) (Fig. 5B), and the 
Figure 4. MRI finding in 3 patients. (A) T1-weighted images after intravenous 
application of gadolinium-DTPA (Gd-DTPA) before (left panel) and after 
6 weeks on the ketogenic diet (KD) (right panel) in axial (upper) and coronar 
(lower) planes of the patient with a minor response. (B) T1-weighted images 
after intravenous application of Gd-DTPA before (left panel) and after 
6 weeks on the ketogenic diet (right panel) in axial directions of a patient with 
stable disease. (C) Fluid-atenuated inversion recovery (FLAIR) images and 
T1-weighted images after application of Gd-DTPA before (left panel) and 
6 weeks after start of bevacizumab (BEV) in a patient with partial response 
to bevacizumab who continued the diet.
Figure 5. Analysis of PFS. (A) PFS of patients on diet who achieved stable 
ketosis as defined as urine ketosis in >50% of measurements (n=8) compared 
to those patients who did not achieve stabile ketosis (n=5) was analysed by 
Kaplan-Meier analysis (p=0.069, log-rank-test). (B) PFS of patients who 
received bevacizumab while on ketogenic diet (n=7) vs. a cohort of patients 
who were treated in the same period of time with bevacizumab but without 
ketogenic diet (n=28) (p=0.38, log-rank test).
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response rate was 65% (17/26 evaluable patients), (comparison 
of the response rates bevacizumab and diet vs. bevacizumab: 
p=0.4, Fisher's exact test).
Combination of a ketogenic diet and bevacizumab in an 
orthotopic glioma model. The high response rate to bevaci-
zumab in patients progressing on the diet led us to explore 
whether a low carbohydrate, ketogenic diet would modulate 
the efficacy of bevacizumab in the U87MG orthotopic glioma 
model. The ketogenic diet led to a significant elevation of 
3-OHB levels (Fig. 6A) indicating pronounced ketosis in the 
animals fed the ketogenic diet. Basal glucose levels were not 
different between the two diet groups (not shown). Importantly, 
whereas the ketogenic diet alone had no significant effect on 
survival, the combination of ketogenic diet and bevacizumab 
prolonged survival compared to bevacizumab alone (median 
survival 52 vs. 58 days, p<0.05, log-rank test, Fig. 6B). Tumor 
volumes analysed by MRI similarly tended to be smaller with 
the combination (standard diet + bevacizumab, 23.9 mm3 vs. 
ketogenic diet + bevacizumab, 13.8 mm3; p>0.05) (Fig. 6C). 
To investigate whether the ketogenic diet modulated metabolic 
parameters, the contents of glucose, lactate and ATP in three 
tumor tissue slices in three mice per group was analysed. 
While there was no significant difference in glucose and lactate 
between groups, treatment with bevacizumab signficantly 
reduced ATP levels within the tumor tissue in both diet groups 
(standard diet vs. standard diet + bevacizumab: p=0.047; keto-
genic diet vs. ketogenic + bevacizumab p=0.017), and there 
was again a trend for a stronger effect of bevacizumab in the 
ketogenic diet-treated animals (Fig. 6D).
Discussion
In the present study, the unrestricted ketogenic diet was safe 
and relatively well tolerated (Table III, Figs. 2 and 3). Three 
patients discontinued the diet in the absence of tumor progres-
sion for poor tolerability. In the remaining 17 patients, ketosis 
was achieved in 12 of 13 evaluable patients. In two patients, 
Figure 6. Mouse xenograft experiments. (A) 3-OHB levels in the blood were determined 24 days after U87MG tumor cell inoculation in mice on standard 
diet (SD) or ketogenic diet (KD) treated with PBS (control) or bevacizumab (BEV). (B) Kaplan-Meier analysis of the treatment groups. (C) At day 28 after 
tumor cell inoculation, 3 mice per group were analysed by MRI. Upper panel, representative T2-weighted images and T1-weighted images after infusion of 
Gd-DTPA are shown. Lower panel, tumor volumes were measured as described, and individual (dot) and mean values (bar) are indicated. (D) Upper panel, 
representative hematoxylin-eosin stainings (H&E) and color-coded distribution of ATP concentrations in representative slices. Lower panel, ATP content in 
the tumor areas was quantified, and individual (dot) and mean values (bar) are shown.
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despite apparently strong adherence to diet as monitored by 
the nutritional questionnaires, no or nearly no ketosis (ketosis 
in 0 and 3% of measurements, Fig. 2) was achieved, indicating 
that there might be genetic or other unknown factors affecting 
the shift to a ketotic state by the applied unrestricted ketogenic 
diet. No severe toxicity was observed, as indicated by the 
absence of serious diet-related adverse events and unchanged 
routine laboratory parameters. Furthermore, weight loss, 
although being statistically significant, was only weak.
The limited number of patients, absence of randomiza-
tion and lack of a control group in the study do not allow 
an unequivocal estimation of efficacy of the ketogenic diet. 
However, it appears that single agent activity, if any, in these 
heavily pretreated patients was moderate at best. Although 
three patients achieved a stable disease at 6 weeks, median 
PFS was only 5 weeks, and PFS at 6 months was 0%.
One important reason for the low clinical activity might be 
the failure to significantly lower glucose levels by the ketogenic 
diet (Table III). Causes for it may involve the frequent use of 
steroids in these patients (Table III) and the fact that no calorie 
restriction was applied. Another explanation might be the 
assumption that tumor cells could circumvent reduced glucose 
availability by the use of ketone bodies. However, we previously 
showed that glioma cell lines, in contrast to rat hippocampal 
neurons, are not capable of metabolizing ketone bodies (36). 
Accordingly, a recent study showed that the expression levels 
of the ketone body-metabolizing enzymes succinyl-CoA 
3-oxoacid CoA transferase (OXCT1) and 3-hydroxybutyrate 
dehydrogenase 1 (BDH1) are reduced in glioma tissue (37).
Because ketone body metabolism requires oxygen for 
energy production via oxidative phosphorylation, and because 
hypoxic tumor cells are more susceptible to glucose restriction 
(38), the ketogenic diet could provide hypoxic tumor areas 
with a specific disadvantage concerning energy metabolism. 
Prolonged anti-angiogenic treatment probably increases 
hypoxia as reflected by upregulated expression of HIF-1α 
and carbonic anhydrase 9 (39-41) and by a decrease of T2' 
values in MRI indicative of a higher proportion of deoxy-
hemoglobin (42-44). Combining low-carbohydrate diets with 
these therapies could therefore act synergistically. Although 
patient numbers are small, we noted a high response rate 
to bevacizumab in patients on the diet that may or may not 
have been achieved with bevacizumab alone. The results of 
the mouse model suggest increased efficacy of the combined 
treatment (Fig. 5). A significant decrease of ATP levels accom-
panied by unaltered glucose concentrations in the tumor tissue 
of bevacizumab-treated mice could indicate that glucose 
levels in the tumor are insufficient to sustain ATP production. 
One reason might be a lack of oxygen leading to less efficient 
ATP generation by suppressed oxidative phosporylation and 
therefore increased glucose needs (5,7,38). Microdialysis 
analyses have shown a correlation between systemic glucose 
concentrations and glucose levels within the glioma tissue 
(11). Although in our and other mouse models (45) basal blood 
glucose levels remained unchanged between the different 
diet groups, postprandial glucose peaks could be reduced by 
carbohydrate-restricted meals (46). The prevention of transient 
glucose excess may therefore be a mechanism contributing to 
the enhancement of bevacizumab's efficacy by the ketogenic 
diet in in the mouse xenograft experiments and the trend in the 
combination-treated patients. As peak glucose concentrations 
were not determined in the patients of the ERGO study, this 
explanation remains speculative, however. Alternatively, since 
ketogenic diet may have pleiotropic effects on tumor cells or 
surrounding glia cells, it may cause a more bevacizumab-
sensitive phenotype via a yet-to-be-defined metabolic switch 
or alterations in the tumor microenvironment.
Various attempts have been made to enhance the efficacy of 
a ketogenic diet. Although activity of an unrestricted ketogenic 
diet alone has been described in the GL-261 glioma model 
(26), calorie restriction was required for efficacy in the CT-2A 
glioma model (24,47). Calorie restriction is known to inhibit 
tumor growth in a variety of other xenograft tumor models 
(48-50). In the ERGO study, no calorie restriction was applied 
considering that it might be unethical to continuously reduce 
calorie intake for several weeks in tumor patients in a palliative 
situation. However, given the wealth of preclinical experiences, 
the clinical efficacy of the ketogenic diet might be increased 
even by transient calorie restriction. In addition, the combi-
nation of calorie restriction or fasting with other therapeutic 
modalities such as chemotherapy or radiotherapy is effective 
in mouse xenograft models (51,52). As a first, preliminary indi-
cation of feasibility and efficacy, an impressive response has 
been reported in a glioma patient who received radiotherapy 
and chemotherapy together with a calorie-restricted ketogenic 
diet (53). Further randomized clinical trials are warranted 
to clarify whether calorie-resticted ketogenic diets might be 
clinically efficient antitumor strategies.
In conclusion, we report that the ketogenic diet can be 
safely applied to glioblastoma patients. Pilot animal data indi-
cate increased acitivity of bevacizumab when combined with 
the ketogenic diet. Additional research on the mechanisms of 
the diet combined with antiangiogenic or vascular targeted 
treatments or conventional therapies are necessary to clarify 
a possible role of the ketogenic diet for glioblastoma therapy.
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